作者
C Maxwell Beck,Pedro Costa‐Pinheiro,David Beale,Madison L. Hollawell,Ryan Lingerak,Fengqi Chang,Grace Azevedo,Amber Medeiros,Riya Patel,Christopher N Zelonis,Sahand Adib,Cassie Kline,Robert J. Wechsler‐Reya,Adam C. Resnick,Phillip B. Storm,Mateusz Koptyra
摘要
Abstract Medulloblastoma (MB), the most common malignant pediatric brain tumor, comprises four molecular subgroups with distinct genetic and clinical features, posing a major challenge for precision medicine. We established over 30 patient-derived tumoroid (PDT) models from surgical specimens spanning all four MB subgroups, demonstrating robust in vitro viability, high fidelity to original tumors, and suitability for biobanking. Histological and immunofluorescence analyses confirm retention of key architectural and molecular features, while transcriptomic (RNA-seq) and DNA methylation profiling show high concordance with primary tissue and accurate subgroup classification, supporting their fidelity. To evaluate their utility for precision oncology, we performed comparative therapeutic testing using the chemotherapeutic etoposide and the FDA-approved, second-generation proteasome inhibitor ixazomib, motivated by evidence of proteasome pathway dependency in aggressive pediatric brain tumors despite limited evaluation in MB. Recognizing the complexity of 3D model testing, we assessed the impact of culture conditions (torque, plate type, number of tumoroids per well) on PDT phenotype and transcriptional state. PDTs exhibited dose-dependent responses to both agents. Drug response metrics, including IC50 values and tumoroid integrity, varied significantly (p < 0.05) from 96-well to 6-well culture format. RNA-seq analysis revealed substantial transcriptional shifts between plate formats: 6-well plates were enriched for proliferative programs, whereas those in 96-well plates exhibited increased expression of metabolic and homeostatic pathways. Plate-driven transcriptional states were recapitulated in the divergent IC50 profiles of both etoposide and ixazomib, two agents with distinct mechanisms of action, suggesting that culture format shapes tumor cell state, thereby impacting drug sensitivity. Collectively, our findings establish medulloblastoma PDTs as a scalable, biologically and clinically relevant platform for precision oncology and functional therapeutic testing. We demonstrate that experimental conditions influence tumor cell state and drug sensitivity, underscoring the importance of standardized tumoroid culture and assay frameworks for reproducible, clinically relevant tumoroid-based drug-response studies in pediatric oncology.